Stableford Capital II LLC Invests $459,000 in COMPASS Pathways PLC Sponsored ADR $CMPS

Key Points

• Stableford Capital II LLC invested $459,000 in COMPASS Pathways PLC, acquiring 163,941 shares, which represents about 0.18% of the company.
• Multiple hedge funds have increased their positions in COMPASS Pathways, with Vivo Capital LLC leading by increasing its stake by 109.1%.
• COMPASS Pathways recently reported an EPS of ($0.38), slightly missing analyst expectations, and has a consensus price target of $16.00 from research analysts.

Stableford Capital II LLC bought a new position in COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 163,941 shares of the company's stock, valued at approximately $459,000. Stableford Capital II LLC owned approximately 0.18% of COMPASS Pathways as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Vivo Capital LLC increased its position in COMPASS Pathways by 109.1% in the first quarter. Vivo Capital LLC now owns 3,362,385 shares of the company's stock worth $9,616,000 after purchasing an additional 1,754,385 shares during the last quarter. Nantahala Capital Management LLC increased its position in COMPASS Pathways by 182.9% in the first quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company's stock worth $8,092,000 after purchasing an additional 1,829,232 shares during the last quarter. ARK Investment Management LLC increased its position in COMPASS Pathways by 4.0% in the first quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company's stock worth $5,162,000 after purchasing an additional 68,601 shares during the last quarter. GMT Capital Corp increased its position in COMPASS Pathways by 15.1% in the first quarter. GMT Capital Corp now owns 1,781,718 shares of the company's stock worth $5,096,000 after purchasing an additional 233,918 shares during the last quarter. Finally, Woodline Partners LP increased its position in COMPASS Pathways by 279.9% in the first quarter. Woodline Partners LP now owns 1,754,856 shares of the company's stock worth $5,019,000 after purchasing an additional 1,292,927 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company's stock.

COMPASS Pathways Stock Down 0.1%

NASDAQ:CMPS opened at $6.83 on Thursday. COMPASS Pathways PLC Sponsored ADR has a 1-year low of $2.25 and a 1-year high of $7.09. The company has a 50-day moving average of $5.16 and a 200 day moving average of $4.27. The firm has a market cap of $655.27 million, a PE ratio of -3.71 and a beta of 2.21. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.82 and a quick ratio of 8.82.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). As a group, research analysts anticipate that COMPASS Pathways PLC Sponsored ADR will post -2.33 EPS for the current fiscal year.

Analyst Ratings Changes

CMPS has been the topic of several research reports. BTIG Research boosted their price target on shares of COMPASS Pathways from $7.00 to $14.00 and gave the stock a "buy" rating in a research report on Monday. Weiss Ratings reiterated a "sell (d-)" rating on shares of COMPASS Pathways in a research report on Wednesday, October 8th. Evercore ISI reiterated an "in-line" rating and set a $6.00 price objective (down previously from $11.00) on shares of COMPASS Pathways in a research report on Monday, June 23rd. Canaccord Genuity Group reiterated a "buy" rating and set a $15.00 price objective on shares of COMPASS Pathways in a research report on Friday, August 1st. Finally, HC Wainwright cut their price objective on shares of COMPASS Pathways from $45.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, August 4th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $16.00.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

Want to see what other hedge funds are holding CMPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.